New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 23, 2013
07:12 EDTALNYAlnylam announces positive results from ALN-TTRsc Phase 1 trial
Alnylam Pharmaceuticals announced positive interim results from its Phase I clinical trial of ALN-TTRsc. Results show that ALN-TTRsc administration led to robust, consistent, and statistically significant knockdown of serum TTR protein levels of up to 94%. In addition, knockdown of TTR, the disease causing protein in ATTR, was found to be rapid, dose dependent, and durable. To date, ALN-TTRsc has been found to be generally safe and well tolerated in this study. These human data are the first to be presented for Alnylamís proprietary GalNAc-siRNA conjugate delivery platform, enabling subcutaneous dosing of RNAi therapeutics with a wide therapeutic index, and demonstrate human translation for this platform. Moreover, these results establish a new benchmark for consistent TTR knockdown of approximately 90% for RNA therapeutics in development for the treatment of ATTR. Upon completion of this Phase I trial, the company expects to start a pilot Phase II clinical study of ALN-TTRsc in FAC patients in late 2013 and, assuming positive results, plans to start a pivotal Phase III trial with ALN-TTRsc in FAC patients in 2014
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 30, 2015
15:50 EDTALNYAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
12:59 EDTALNYFly Watch: Medicines Co., Alnylam rise ahead of cholesterol study presentation
Subscribe for More Information
August 26, 2015
07:09 EDTALNYVertex, Novavax among select biotechs to buy on weakness, says Piper Jaffray
Subscribe for More Information
August 24, 2015
11:43 EDTALNYThe Medicines Co. and Alnylam Pharmaceuticals hold a joint conference call
Subscribe for More Information
August 20, 2015
07:31 EDTALNYAlnylam Pharmaceuticals to hold a roundtable
Final Roundtable in a series of online "RNAi Roundtables" entitled, "Patisiran & Revusiran for Treatment of Transthyretin (TTR)-Mediated Amyloidosis", consisting of presentations by Alnylam scientists, clinical collaborators and patient advocates review recent progress in many of the company's development-stage pipeline programs will be held on August 20 at 9 am. Webcast Link
August 17, 2015
06:22 EDTALNYPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use